Business
Basilea provides portfolio update and outlook
Clinical portfolio strengthened through the in-licensing of phase 3-ready antibiotic ceftibuten-ledaborbactamFosmanogepix second phase 3 study initiated; two phase 3 studies in invasive fungal infections progressing as plannedTwo new preclinical collaborations to develop novel antibacterial and antifungal drugsCresemba continued strong double-digit in-market sales growth Allschwil, Switzerland, January 08, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutica
About this update from Basilea Pharmaceutica Ag
[{"type":"image","alt":"Basilea Pharmaceutica AG, Allschwil","displaySize":"","headline":null,"caption":"Basilea Pharmaceutica AG, Allschwil","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/a45f97ddaed549237a3a9f58773435b7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/863aV4U6H3aPDpGW_iaFpg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a45f97ddaed549237a3a9f58773435b7","width":300,"height":102}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Clinical portfolio strengthened through the in-licensing of phase 3-ready antibiotic ceftibuten-ledaborbactam","length":109,"tagName":"p"}]},{"val":[{"type":"text","content":"Fosmanogepix second phase 3 study initiated; two phase 3 studies in invasive fungal infections progressing as planned","length":117,"tagName":"p"}]},{"val":[{"type":"text","content":"Two new preclinical collaborations to develop novel antibacterial and antifungal drugs","length":86,"tagName":"p"}]},{"val":[{"type":"text","content":"Cresemba continued strong double-digit in-market sales growth","length":61,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":373,"olType":false},{"type":"text","content":"Allschwil, Switzerland, January 08, 2026","length":40,"tagName":"p"},{"type":"text","content":"Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today on the progress within its R&D and commercial portfolio during 2025 and outlined the upcoming milestones and timelines.","length":321,"tagName":"p"},{"type":"text","content":"David Veitch, Chief Executive Officer, highlighted: "We entered 2025 from a position of strength and closed the year even stronger, thanks to outstanding execution and significant progress across all fronts. During 2025, we delivered on every goal we set.”","length":261,"tagName":"p"},{"type":"text","content":"He continued: “Cresemba celebrated its 10th year on the market with continued commercial success, achieving strong global in-market sales and expanding its reach to more than 75 countries. Zevtera was successfully launched in the US, its commercially most important market, while our R&D pip...